Philadelphia, January 11, 2018 - A new study by researchers at Roche in Basel, Switzerland has identified a key brain region of the neural circuit that controls social behavior. Increasing the activity of this region, called the habenula, led to social problems in rodents, whereas decreasing activity of the region prevented social problems.
The study, which appears in Biological Psychiatry, suggests that social impairments characteristic of autism spectrum disorder may stem from alteration of activity in this circuit, and that tuning this circuit may help treat the social deficits in the disorder.
"We are excited about this study as it identifies a brain circuit that may play a critical role in social reward, which is affected in autism," said senior author Dr. Anirvan Ghosh, who was the Head of Neuroscience Research at Roche and now serves as Head of Research and Early Development at Biogen. The findings provide clues as to what may be altered in the brain to lead to neurodevelopmental conditions like autism spectrum disorder.
Previous research has linked social function to the prefrontal region of the brain, but circuits that affect prefrontal control of social behavior were unknown. So first author Dr. Madhurima Benekareddy and colleagues activated the prefrontal region in mice and rats, and performed a brain-wide screen to find which regions responded. The screen identified changes in activity in regions related to emotional behavior, particularly in the habenula.
In the study, the researchers then used a combination of different techniques to map the connections from the habenula to the frontal area of the brain, and to precisely control the activity of neurons in these regions. Turning up the activity of neurons in the habenula reduced how much the rats and mice socialized. Turning down habenula activity prevented the social deficits that could be induced by activating the frontal region.
According to the authors, an alteration of the normal activity range for the circuit may cause behavioral function in disorders such as autism spectrum disorder. "Understanding how altered brain function leads to social deficits could help develop novel targeted therapeutics for autism spectrum disorder," said Ghosh, such as by tuning the circuit to correct the altered activity.
The findings also have implications for diseases other than autism spectrum disorder, including schizophrenia and depression. The circuit incorporates brain regions involved in reward and pleasure, leading the authors to consider that social dysfunction may stem from reduced enjoyment in social interaction. "It is interesting that the circuit implicated in social behavior in this study is also a circuit implicated in the biology of depression," said Dr. John Krystal, Editor of Biological Psychiatry. "Perhaps this circuit represents a pathway through which disruptions in social relationships contribute to negative mood states and depression."
Notes for editors
The article is "Identification of a cortico-habenular circuit regulating socially-directed behavior," by Madhurima Benekareddy, Tevye Jason Stachniak, Andreas Bruns, Frederic Knoflach, Markus von Kienlin, Basil Künnecke, and Anirvan Ghosh (http://dx.
Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at Biol.Psych@UTSouthwestern.edu or +1 214 648 0880. Journalists wishing to interview the authors may contact Anirvan Ghosh at firstname.lastname@example.org.
The authors' affiliations and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 6th out of 142 Psychiatry titles and 10th out of 258 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2016 Impact Factor score for Biological Psychiatry is 11.412.
Elsevier is a global information analytics business that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, Scival, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. http://www.
Editorial Office, Biological Psychiatry
+1 214 648 0880